BackYubo International Biotech Limited Overview

Yubo International Biotech Limited EBIT

Track Yubo International Biotech Limited's EBIT ($-810K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$203.73K
↑ 34.31% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$808.80K
↑ 41.4% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Yubo International Biotech Limited (YBGJ) FAQ

The latest EBIT for YBGJ is $-810K as of September 2026. That compares with $-1.4M in the prior-year period — up 41.4% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Yubo International Biotech Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, YBGJ's EBIT moved from $-1.4M to $-810K — a 41.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Yubo International Biotech Limited's operating scale or balance-sheet position.

Against its sector companies, YBGJ currently prints $-810K for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Yubo International Biotech Limited's growth, margins, and balance sheet.

A EBIT figure of $-810K for YBGJ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting YBGJ's EBIT ($-810K), review year-over-year change from $-1.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.